Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells
Nurix to receive a $60 million upfront payment, in addition to the potential for approximately $3.4 billion in milestone payments plus future royalties
Nurix retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration
Nurix to host a conference call today, September 7 at 8:30 a.m. ET
At 8:30 a.m., ET, September 7, 2023, Nurix will host a conference call and webcast to discuss this update. The live webcast, with an accompanying presentation, will be accessible under the Events and Presentations page in the Investors section of the company’s website here. To participate in the live conference call, please follow this link. A replay of the webcast and call will be archived on the Nurix website for approximately 30 days after the event.
https://finance.yahoo.com/news/nurix-announces-strategic-collaboration-seagen-110000783.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.